FDA
-
-
-
-
-
-
-
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
-
-
-
-
-
-
-
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, atĀ the Inaugural Interdisciplinary Meeting on Anti
-
-
-
-
-
-
-
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
-
-
-
-
-
-
-
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
-
-
-
-
-
-
-
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
-
-
-
-
-
-
-
SCYNEXIS Reports Second Quarter 2024 Financial ResultsĀ and Provides Corporate Update
-
335,753 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


